Effects of gyrA and parC mutations in quinolones resistant clinical gram negative bacteria from Nigeria

African Journal of Biomedical Research

Volumn 15, Issue 2, 2012, Pages 97-104

  Ogbolu, D O ^a,b   Daini, O A ^c   Ogunledun, A ^c   Terry Alli, A O ^a   Olusoga Ogbolu, F F ^c   Webber, M A ^b  

^a LADOKE AKINTOLA UNIVERSITY OF TECHNOLOGY   (Nigeria)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c OLABISI ONABANJO UNIVERSITY   (Nigeria)

Author keywords

Bacteria; Mutation; Nigeria; Quinolones; Topoisomerase

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARAGINE; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GENTAMICIN; LEUCINE; NALIDIXIC ACID; OFLOXACIN; PEFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; SPARFLOXACIN; TETRACYCLINE; THREONINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ESCHERICHIA COLI; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GRAM NEGATIVE BACTERIUM; GYRA GENE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NIGERIA; NONHUMAN; PARC GENE; POLYMERASE CHAIN REACTION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA;

EID: 84875041220     PISSN: 11195096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bachoual R, Tankovic J, Soussy CJ (1998): Analysis of the mutations involved in fluoroquinolone ressistance of in-vivo and in-vitro mutants of Escherichia coli. Microb Drug Resist 4, 271-276.
2. Chen CR, Malik M, Snyder M and Drlica K (1996): DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. Journal Molecular Biology 258, 627-637.
3. Chen JY, Siu LK, Chen YH, Lu PL, Ho M, Perg CF (2001): Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from Taiwan medical center. Microbiology Drug Resistance 7, 47-53.
4. Daini OA, DO Ogbolu and A Ogunledun (2006): Plasmid determined resistance to quinolones in clinical isolates of Gram negative bacilli African Journal Medicine & Medical Sciences 35, 437-441.
5. Eaves DJ, Liebana E, Woodward MJ and Piddock LJV (2002): Detection of gyrA mutation in Quinolone-resistant Salmonella enterica by Denaturing High-Performance Liquid Chromatography. Journal Clinical Microbiology 40 (11), 4121-4125.
6. Fendukly F, Karlsson I, Hanson HS, Kronvall G, Dornbusch K (2003): Patterns of mutations in target genes in septicaemia isolates of Escherichia coli and Klebsiella pneumoniae with resistance or reduced susceptibility to ciprofloxacin. APMIS 111, 857-866.
7. rdedn. Washington, DC: American Society for Microbiology Press 41-67.
8. Hopkin KL, Davies RH, Threlfall EJ (2005): Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int J Antimicrob Agents 2, 358-373.
9. Jacoby GA (2005): Mechanisms of resistance to quinolones. Clinical Infectious Diseaes 41(Suppl 2): S120-S126.
10. Komp LP, Karlsson A, Hughes D (2003): Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 47, 3222-3232.
11. Ling JM, Chan EW, Lam AW and Cheng AF (2003): Mutations in topoisomerase genes of fluoroquinoloneresistant salmonella in Hong Kong. Antimicrob Agents Chemother 47 (11), 3567-3573.
12. Ling TK, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM (2006): Multicenter antimicrobial susceptibility survey of Gram negative bacteria isolated from patients with community-acquired infections in the People's Republic of China. Antimicrob Agents Chemother 50, 374-378.
13. Martinez-Martinez L, Pascual A, Garcia I, Tran J, Jacoby GA (2003): Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother 51, 1037-1039.
14. Murphy OM, Marshell C, Stewart D, Freeman R (1997): Ciprofloxacin-resistant Enterobacteriaceae Lancet 349, 1028-1029.
15. Ogbolu DO, Daini OA, Ogunledun A, Alli AO and Webber MA (2011): High levels of multidrug resistance in clinical isolates of Gram-negative pathogens from Nigeria. Int J Antimicrob Agents 37, 62-66.
16. Oni AA, RA Bakare, AO Arowojolu, RA Toki and NA Fasina (2001): Comparative in-vitro activities of commonly available quinolones and other antibiotics on bacteria isolates in Ibadan, Nigeria. African Journal Medicine & Sciences 30, 35-37.
17. Ozeki S, Deguchi T, Yasuda M, Nakano M, Kawamura T, Nishino Y and Kawada Y (1997): Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. Journal Clinical Microbiology 35, 2315-2319.
18. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC (2006): Prevalence of aac(6') lb-cr encoding a ciprofloxacinmodifying enzyme in the United States. Antimicrob Agents Chemother 50 (11), 3953-55.
19. Pazhani GP, Niyogi SK, Singh AK, Sen B, Taneja N, Kundu M, Yamasaki S and Ramamurthy T (2008): Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India. Journal of Medical Microbiology 57, 856-863.
20. Peng H, Marians KJ (1993): Escherichia coli Topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions J. Biol Chem 268, 24481-90.
21. Piddock LJ (2002): Fluoroquinolone resistance in salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 26, 3-16.
22. Piddock LJV (2006): Multidrug-resistance efflux pumps-not just for resistance. Nature Reviews Microbiology 4, 629-36.
23. Poole K (2005): Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56, 20-51.
24. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC (2006): Qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates in the United States. Antimicrob Agents Chemother 50, 2872-74.
25. Ruiz J (2003): Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51: 1109-17.
26. Ruiz J, Gomez J, Navia MM, Ribera A, Sierra JM, Marco F (2002): High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagnostics Microbiology and infectious Disease 42, 257-61.
27. Saenz Y, Zarazaga M, Brinas L, Ruiz-Larrea F, Torres C (2003): Mutations in gyrA and parC genes in nalidixic acidresistant Escherichia coli strains from food products, humans and animals. J Antimicrob Chemother 51, 1001-5.
28. Soge OO, Adeniyi BA, Roberts MC (2006): New antibiotic resistance genes associated with CTX-M plasmids from uropathogenic Nigerian Klebsiella pneumoniae. J Antimicrob Chemother 58(5), 1048-1053.
29. Tavio MM, Vila J, Ruiz J, Martinez-Sanchez AM and Jimenez de Anta MT (1999): Mechanism involved in the development of resistance to fluoroquinolones in Escherichia coli strains. J Antimicrob Chemother 44, 735-42.
30. Threlfall EJ, Cheasty T, Graham A, Rowe B (1997): High level resistance to ciprofloxacin in Escherichia coli Lancet 349, 403.
31. Wang M, Sahm DF, Jacoby GA, Zhang Y, Hooper DC (2004): Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmidmediated quinolone resistance determinant qnr. Antimicrob Agents Chemother 48, 1400-01.
32. Webber MA and Piddock LJV (2001): Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolones-resistant clinical and veterinary isolates of Escherichia coli. Antimicrob Agents Chemother 45, 1550-2.
33. Weigel LM, Steward CD, Tenover FC (1998): gyrA mutations associated with fluoroquinolones resistance in eight species of Enterobacteriaceae. Antimiicrob Agents Chemother 42, 2661-7.
34. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, Konda T, and Arakawa Y (2007): New plasmid-mediated fluoroquinolones efflux pump, qepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 51(9), 3354-3360.